Literature DB >> 17210842

Accelerated mitochondrial adenosine diphosphate/adenosine triphosphate transport improves hypertension-induced heart disease.

Thomas Walther1, Carsten Tschöpe, Anja Sterner-Kock, Dirk Westermann, Silvia Heringer-Walther, Alexander Riad, Alen Nikolic, Yong Wang, Linda Ebermann, Wolf-Eberhard Siems, Michael Bader, Mehdi Shakibaei, Heinz-Peter Schultheiss, Andrea Dörner.   

Abstract

BACKGROUND: Strong evidence suggests that mitochondrial malfunction, which leads to disturbed energy metabolism and stimulated apoptosis, is a linchpin in the induction and manifestation of cardiac failure. An adequate exchange of ATP and ADP over the inner mitochondrial membrane by the adenine nucleotide translocase (ANT) is thereby essential to guarantee the cellular energy supply. METHODS AND
RESULTS: To explore the effect of an ameliorated mitochondrial ATP/ADP transportation on cardiac dysfunction, we generated transgenic rats overexpressing ANT1 in the heart (ANT rats) and crossed them with renin-overexpressing rats (REN rats) suffering from hypertension-induced cardiac insufficiency. Cardiac-specific ANT1 overexpression resulted in a higher ATP/ADP transportation and elevated activities of respiratory chain complexes. Increased ANT activity in double-transgenic (ANT/REN) animals did not influence excessive hypertension seen in REN rats. Hypertension-induced cardiac hypertrophy in the REN rats was prevented by parallel ANT1 overexpression, however, and left ventricular function remarkably improved. The ANT1 overexpression led to a reduction in fibrosis and an improvement in cardiac tissue architecture. Consequently, the survival rate of ANT/REN rats was enhanced. Further investigations into the cardioprotective mechanism of ANT1 overexpression revealed improved mitochondrial structure and function and significantly reduced apoptosis in ANT/REN rats, shown by lowered cytosolic/mitochondrial cytochrome c ratio, reduced caspase 3 level, and prevented DNA degradation.
CONCLUSIONS: Myocardial ANT1 overexpression protects against hypertension-induced cardiac pathology. Thus, the improvement in mitochondrial function may be a basic principle for new strategies in treating heart disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17210842     DOI: 10.1161/CIRCULATIONAHA.106.643296

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  27 in total

Review 1.  Anti-apoptosis in nonmyocytes and pro-autophagy in cardiomyocytes: two strategies against postinfarction heart failure through regulation of cell death/degeneration.

Authors:  Genzou Takemura; Hiromitsu Kanamori; Hideshi Okada; Nagisa Miyazaki; Takatomo Watanabe; Akiko Tsujimoto; Kazuko Goto; Rumi Maruyama; Takako Fujiwara; Hisayoshi Fujiwara
Journal:  Heart Fail Rev       Date:  2018-09       Impact factor: 4.214

Review 2.  Mitochondrial membrane transporters and metabolic switch in heart failure.

Authors:  Vikas Kumar; T R Santhosh Kumar; C C Kartha
Journal:  Heart Fail Rev       Date:  2019-03       Impact factor: 4.214

Review 3.  Mitochondria and cardiovascular diseases-from pathophysiology to treatment.

Authors:  Gerasimos Siasos; Vasiliki Tsigkou; Marinos Kosmopoulos; Dimosthenis Theodosiadis; Spyridon Simantiris; Nikoletta Maria Tagkou; Athina Tsimpiktsioglou; Panagiota K Stampouloglou; Evangelos Oikonomou; Konstantinos Mourouzis; Anastasios Philippou; Manolis Vavuranakis; Christodoulos Stefanadis; Dimitris Tousoulis; Athanasios G Papavassiliou
Journal:  Ann Transl Med       Date:  2018-06

4.  ATP-ADP translocase and effects on ischemic heart.

Authors:  Friedrich C Luft
Journal:  J Mol Med (Berl)       Date:  2016-06       Impact factor: 4.599

Review 5.  Is Mitochondrial Dysfunction a Common Root of Noncommunicable Chronic Diseases?

Authors:  Alexis Diaz-Vegas; Pablo Sanchez-Aguilera; James R Krycer; Pablo E Morales; Matías Monsalves-Alvarez; Mariana Cifuentes; Beverly A Rothermel; Sergio Lavandero
Journal:  Endocr Rev       Date:  2020-06-01       Impact factor: 19.871

Review 6.  Molecular switches under TGFβ signalling during progression from cardiac hypertrophy to heart failure.

Authors:  J Heger; R Schulz; G Euler
Journal:  Br J Pharmacol       Date:  2015-11-16       Impact factor: 8.739

7.  Identification of an Epitope from Adenine Nucleotide Translocator 1 That Induces Inflammation in Heart in A/J Mice.

Authors:  Rakesh H Basavalingappa; Chandirasegaran Massilamany; Bharathi Krishnan; Arunakumar Gangaplara; Guobin Kang; Vahid Khalilzad-Sharghi; Zhongji Han; Shadi Othman; Qingsheng Li; Jean-Jack Riethoven; Raymond A Sobel; David Steffen; Jay Reddy
Journal:  Am J Pathol       Date:  2016-12       Impact factor: 4.307

Review 8.  The molecular composition of the mitochondrial permeability transition pore.

Authors:  Christopher P Baines
Journal:  J Mol Cell Cardiol       Date:  2009-02-20       Impact factor: 5.000

9.  Cardiac phenotype and angiotensin II levels in AT1a, AT1b, and AT2 receptor single, double, and triple knockouts.

Authors:  Joep H M van Esch; Florian Gembardt; Anja Sterner-Kock; Silvia Heringer-Walther; Thu H Le; Dirk Lassner; Theo Stijnen; Thomas M Coffman; Heinz-Peter Schultheiss; A H Jan Danser; Thomas Walther
Journal:  Cardiovasc Res       Date:  2010-01-12       Impact factor: 10.787

10.  A mitochondrial mutation A4401G is involved in the pathogenesis of left ventricular hypertrophy in Chinese hypertensives.

Authors:  Hai-Yan Zhu; Shi-Wen Wang; Li Liu; Yan-Hua Li; Rui Chen; Lin Wang; C James Holliman
Journal:  Eur J Hum Genet       Date:  2008-08-13       Impact factor: 4.246

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.